UNDERSTANDING ARTHRITIS

Biosimilars

Learn more about biosimilars, affordable medicines that reduce inflammation and offer an alternative to biologics. Discover benefits, uses, and resources.

Biosimilars offer a cost-effective way to reduce swelling, providing the same benefits as biologics at about 70% of the cost.
LEARN MORE

What are Biosimilars?

Biosimilars are a type of medicine that can help reduce swelling in the body. These medicines are very similar to other medicines called biologics (or “reference medicine”) that are commonly used. People usually spend about $0.70 on biosimilars for every $1 they would have spent on biologics.

Download our free fact sheet for quick reference and easy sharing

Descargar en español!

Get essential information on fibromyalgia symptoms, diagnosis, treatments, and practical tips to help manage the condition.

YOUR DONATION

How are biosimilars approved and regulated?

Biosimilars are approved by the Food and Drug Administration (FDA) as another option to a current biologic treatment. To evaluate the effectiveness of a biosimilar, the FDA checks its ingredients and how it works compared to the original biologic medicine. The biosimilar is only approved if it is safe and works similarly at treating arthritis and autoimmune disease to the original biologic medicine.

Can I switch from my current biologic treatment to a biosimilar?

You may want to switch from a biologic treatment to an approved biosimilar if the biologic treatment is too expensive or not covered by your insurance. Because biosimilars are very close to their biologics, the biosimilar should have a similar effect on treating your condition and similar side effects.

It is generally safe to switch from a biologic to a biosimilar, but you should get advice from your doctor if you are considering this. They can tell you about available options, risks and benefits, and price.

What biosimilars are approved for arthritis and autoimmune diseases?

This list changes often as new biosimilars are approved. As of June 2023, there are biosimilars for the following autoimmune disease treatments:

Rheumatoid arthritis

adalimumab, infliximab, etanercept

Juvenile idiopathic arthritis

adalimumab, etanercept

Rheumatoid arthritis

adalimumab, etanercept

Ankylosing spondylitis

adalimumab, infliximab, etanercept

Translate »

Connect with ANRF Today!

Stay up -to-date with the latest arthritis news, stories and info.​

Make a Donation

Make a one-time or recurring donation and know that you are making a difference by funding cutting-edge arthritis research.